

0960-894X(94)E0099-Z

SYNTHESIS OF NEW MODIFIED 2',5'-ADENYLATE TRIMERS CARRYING 3'-AMINO-3'-DEOXYADENOSINE AT THE 2'-TERMINUS

Wolfgang Pfleiderer *, Frank Himmelsbach, and Ramamurthy Charubala

Fakultät für Chemie, Universität Konstanz, Postfach 5560, D-78434, Konstanz, Germany.

Abstract: The trimeric 2',5'-linked adenylates 2 and 3 constituting 3'-amino-3'-deoxyadenosine at the 2'-terminal end have been prepared by the phosphotriester and phosphoramidite method. Amino protection was achieved by the p-nitrophenylethoxycarbonyl residue which forms stable carbamate functions cleavable, however, by \(\theta\)-elimination using DBU. The new trimers were characterized by physical means and their biological activity screened regarding antiviral and antitumoral effects.

The unique 2',5'-linked oligoadenylate (2-5A) 1, a product of the action of the interferon-induced enzyme 2-5 A synthetase, interacts with a latent endoribonuclease (RNase L) which can lead to RNA degradation and inhibition of translation ¹. It appears that each individual nucleotide moiety of 2-5 A3 may assume a fundamentally different role in binding to and activation of RNase L ². The 2-5 A molecules are not readily taken up in cell extracts, by the intact eucaryotic cells and are rapidly hydrolysed by an exonucleolytic 2',5'-phosphodiesterase ³ and thus their ability to inhibit protein synthesis is only transitory.

In order to study the interesting 2-5 A system, several analogs of 2-5 A containing modifications primarily on the sugar moiety, on the base and on the internucleotide linkages, respectively, have been synthesised and investigated⁴. Pronounced enzymic stability of the 2-5 A molecules can be achieved by the introduction of either 2-5 phosphorothioate functions ⁵ or the use of cordycepin (3'-deoxyadenosine) as a monomeric building block ⁶. Another approach to counteract the enzymic digestion of the 2-5 A oligonucleotides can be seen in the synthesis of adenylyl-(2'-5')-adenylyl-(2'-5')-3'-amino-3'-deoxyadenosine (2) and cordycepinyl-(2'-5')-adenylyl-(2'-5')-3'-amino-3'-deoxyadenosine (3). This molecule bears at the 2'-terminus a 3'-amino group, which is present at neutral pH in its ammonium state preventing degradation by phosphodiesterases. Compound 2 was first synthesised applying the phosphotriester approach using p-nitrophenylethyl (NPE) and p-nitrophenylethoxycarbonyl (NPEPOC) groups for phosphate and amino protection⁷.

	R	R ¹	R²
1	PPP	он	он
2	н	ОН	МH3
3	н	н	ήн,

The synthetic approach to the trimers 2 and 3 afforded 3'-amino-3'-deoxyadenosine (4)⁸ as a 2'-terminal building block which shows interesting biological activity ⁹ in itself and which had to be suitably protected at its reactive functions. Acetyl, trifluoroacetyl ¹⁰ as well as tert-butoxycarbonyl groups ¹¹ were used in already to block the 3'-amino function but we chose the p-nitrophenylethoxycarbonyl protection for the 3'-amino group since a selective reaction took place on treatment of 3'-amino-3'-deoxyadenosine (4) with the acylating agent 5¹² in dry dimethylformamide due to the high nucleophilicity of the 3'- amino function. Simple dilution of the reaction mixture led to precipitation of the carbamate 6 in almost quantitative yield. For the protection of the 6-amino function the sugar hydroxyls were first silylated with trimethylsilyl imidazole, then treatedwith the acylating agent 5 in dichloromethane to introduce the p-nitrophenylethoxycarbonyl group atthe N⁶ position followed by the removal of the silyl groups with pyridine/ water to give crystalline compound 7 in 81 % overall yield. In subsequent reactions the 5'-hydroxyl group was first selectively monomethoxytritylated in 88 % yield by monomethoxytritylchloride in pyridine, then the tert-butyldimethylsilyl group was introduced at the 2'-hydroxyl position to give compound 9, which on treatment with acid gave finally the required monomeric building block 10 in high overall yield.

The second synthetic component for the formation of 2 was derived from 3'-O-tert-butyldimethylsilyl-5'-O-monomethoxytrityl-N⁶-p-nitrophenylethoxycarbonyl-adenosine (11)^{7,13} which was converted into the corresponding phosphotriester 12 in 85% yield by first phosphorylating with 2,5-dichlorophenylphosphoditriazolide in pyridine and subsequent addition of p-nitrophenylethanol followed by silica gel column chromatography for purification. The fully protected phosphotriester 12 was used as common precursor either for selective deprotection to the corresponding phosphodiester 13 in 92% yield using the oximate method ¹⁴ or by treatment with p-toluenesulfonic acid in dichloromethane and methanol (4/1) to give the 5'-hydroxy phosphotriester 14 in 84 % yield. Both these components 13 and 14 formed on coupling using 2,4,6-triisopropylbenzenesulfonyl chloride and N-methylimidazole in pyridine the fully blocked dimer 15 in 84 % yield which was then transferred by the oximate method into the 2'-terminal phosphodiester 16 also in good yield prone for condensation with the 5'-OH monomer 10 in an analogous manner to achieve 85% of the fully protected trimer 17.

Phosphotriester approach

The same trimer 17 as well as the trimer 24 containing cordycepin at the 5'end and 3'-amino-3'-deoxy-adenosine at the 2' terminus were synthesized via the phosphoramidite approach ¹⁵ since phosphoramidites are more reactive. Compound 11 was converted into the corresponding phosphoramidate 20 by treatment with p-nitrophenylethoxy-bis-N,N-diisopropylaminophosphane 19¹⁶ in presence of tetrazole as catalyst and acetonitrile as solvent at room temperature for 20 h yielding 80% after silica gel column chromatography. Condensation of 20 with 2'-O-tert-butyldimethylsilyl-N⁶,3'-di-p-nitrophenylethoxycarbonyl-3'-amino-3'-deoxyadenosine (10) under tetrazole catalysis in dichloromethane for 3h and subsequent oxidation of the phosphitetriester intermediate with iodine in pyridine/water gave the protected dimer 22 in 85% yield after column chromatographical purification. The 5'-monomethoxytrityl group was then removed with acid to give 23 in 88% isolated yield and the final conversion into the trimer 17 consisted of another condensation between 20 and 23 followed by oxidation and chromatographic isolation of pure material in 90% yield.

Phosphoramidite approach

The synthesis of fully protected cordycepinyl-(2'-5')-adenylyl-(2'-5')-3'amino-3'-deoxydenosine 24 was achieved from 5'-monomethoxytrityl-N⁶-p-nitrophenylethoxycarbonyl-3'-deoxydenosine 18 ¹⁷ as starting material which was converted into the 2'-phosphoramidite derivate 21 in the usual manner using the phosphitylating agent 19 and tetrazole and had been isolated as a diastereomeric mixture in 89% yield. The chain elongation to the trimer 24 resulted from a condensation reaction of 21 and the dimer 23 forming the intermediary phosphitetrister function which was subsequently oxidized by iodine in pyridine / water to the corresponding phosphotriester. As catalyst for phosporamidite activation either tetrazole or 3-nitro-1,2,4-triazole were applied with the same success leading to a final yield of the fully protected trimer 24 in 88% yield after chromatographic isolation and purification.

Both trimers 17 and 24, respectively, were deblocked by the same subsequent sequence of reactions consisting first of acid treatment to liberate the 5'-OH group second by removal of the p-nitrophenylethyl and p-nitrophenylethoxycarbonyl groups in a \(\textit{B}\)-elimation reaction using 0.5 M DBU in pyridine and third by the cleavage of the tert-butyldimethylsilyl groups in 1M tetrabutylammonium fluoride in tetrahydrofurane. Isolation of the fully deblocked trimers 2 and 3 was performed by ion exchange chromatography on DEAE Sephadex A-25 with triethylammonium bicarbonate as the eluent and followed by evaporation and further purification by paperchromatography using the system isopropanol / ammonia / water (6/1/3), elution with water and final lyophilization gave colorless powders in 80 - 85% yield.

The purity of these trimers was checked by TLC and HPLC and their structural characterizations have been done by UV and NMR spectra.




Fig. 1. Purity control of 2 and 3 by HPLC on RP-18 in 0.1 M NH₄OAc/CH₃CN 95:5

Preliminary biological screening experiments have indicated the expected high enzymatic stability of these structures towards phosphodiesterase and an antiviral effect against HIV-1 in peripheral blood mononuclear cells in culture. More detailled studies are in progress.

Acknowledgements: We wish to thank Dr.M.Morr, Braunschweig for the generous gift of 3'-amino-3'-deoxyadenosine and the Fonds der Chemischen Industrie for financial support..

References and Notes

 Torrence, P.F. In Biochemical Response Modifiers. New Approaches to Disease Intervention Academic Press: Orlando; New York, 1985: pp77.

Kerr, I.M.; Brown, R.E. Proc. Natl. Acad. Sci. USA. 1978, 75, 256.

Hovanessian, A.G.; Brown, R.E.; Kerr, I.M. Nature, 1977, 268, 537.

- 2. Torrence, P. F.; Brozda, D.; Alster, D.; Charubala, R.; Pfleiderer, W. J. Biol. Chem. 1988, 263, 1131.
- 3. Williams, B.R.G.; Kerr, J.M. Nature, 1978, 276, 88.
 - Minks, M.A.; Bevin, S.; Maroney, P.A.; Baglioni, C. Nucleic Acids Res. 1979, 6, 767.
- 4. Charubala, R.; Pfleiderer, W. Tetrahedron Lett. 1980, 21, 4077.
 - Charubala, R.; Pfleiderer, W. Heterocycles. 1990, 30, 1141.
 - Charubala, R.; Pfleiderer, W.; Sobol, R.W.; Li, S.W.; Suhadolnik, R.J. Helv. Chim. Acta. 1989, 72, 1354.
 - den Hartog, J.A.J.; Wijnands, R.A.; Van Boom, J.H.; Crea, R. J. Org. Chem. 1981, 46, 2242
 - Jäger, A.; Engels, J. Nucleic Acids Res. 1981, 9, 149.
 - Imai, J.; Torrence, P.F. J. Org. Chem. 1985, 50, 1418.
 - Gosselin, G.; Imbach, J.L. Tetrahedron Lett. 1981, 22, 4699.
 - Herdewijn, P.; Charubala, R.; Declercq, E.; Pfleiderer, W. Helv. Chim. Acta. 1989, 72, 1729.
 - Kannou, M.; Ohmori, H.; Takaku, T.; Yokohama, S.; Kawai, G.; Suhadolnik, R.J.; Sobol, R.W. Jr.
 - Nucleic Acids Res. 1990, 18, 4439.
 - Kwiatkowski, M.; Gioelli, C.; Chattopadhyaya, J.B.; Öberg, B.; Drake, A.F. Chem. Scr. 1982, 19, 49.
 - Mikhailov, S.N.; Charubala, R.; Pfleiderer, W. Helv. Chim. Acta. 1991, 74, 887.
 - Ruf, K.; Pfleiderer, W. Carbohyd. Res. 1991, 216, 421.
 - Scela, F.; Ott, J.; Hißmann, E. Liebig's Ann. Chem. 1984, 692.
 - Jamoulle, J.C.; Imai, J.; Lesiak, K.; Torrence, P.F. Biochemistry. 1984, 23, 3063.
 - Charubala, R.; Pfleiderer, W. Helv. chim Acta. 1992, 75, 471.
- 5. Kariko, K.; Li, S.W.; Sobol, R.W.Jr.; Suhadolnik, R.J.; Charubala, R.; Pfleiderer, W. *Biochemistry*. 1987, 26, 7136.
 - Kariko, K.; Sobol, R.W.; Suhadolnik, L.; Li, S.W.; Reichenbach, N.L.; Suhadolnik, R.J.; Charubala, R.; Pfleiderer, W. Biochemistry. 1987, 26, 7127.
- Charubala, R.; Uhlmann, E.; Himmelsbach, F.; Pfleiderer, W. Helv. Chim. Acta. 1987, 26, 7143.
 Suhadolnik, R.J.; Doetsch, P.W.; Devash, Y.; Henderson, E.E.; Charubala, R.; Pfleiderer, W. Nucleosides & Nucleotides. 1983, 2, 351.
- Pfleiderer, W.; Himmelsbach, F.; Charubala, R.; Schirmeister, H.; Beiter, A.; Schulz, B.; Trichtinger, T. Nucleosides & Nucleotides. 1985, 4, 81.
- 8. Gerber, N.N.; Lechevalier, H.L. J. Org. Chem. 1962, 27, 1731.
 - Reist, E.J.; Baker, B.R. J. Org. Chem. 1958, 23, 1083.
 - Samono, M.C.; Robins, M.J. Tetrahedron Lett. 1989, 30, 2329.
- 9. Suhadolnik, R.J. Nucleoside Antibiotics. Wiley: New York. 1970, pp 76-86.
- 10. Azhayev, A.V.; Krayevsky, A.A.; Smrt, J. Coll. Czechoslov. Chem. Comm. 1978, 43, 1647.
- 11. Morr, M.; Ernst, L. Chem. Ber. 1979, 112, 2815
- 12. Himmelsbach, F.; Schulz, B.S.; Trichtinger, T.; Charubala, R.; Pfleiderer, W. Tetrahedron. 1984, 40, 59.
- 13. Schirmeister, H.; Pfleiderer, W. Helv. Chim. Acta. in press.
- 14. Reese, C.B.; Zard, L. Nucleic Acids Res. 1981, 9, 4611.
- Beaucage, S.L.; Caruthers, M.H. Tetrahedron Lett. 1981, 22, 1859.
 Barone, A.D.; Tang, J.Y.; Caruthers, M.H. Nucleic Acids Res. 1984, 12, 4051.
- Sobol, R.W.; Charubala, R.; Schirmeister, H.; Kon, N.; Pfleiderer, W.; Suhadolnik R.J. J. Biol. Chem. 1993, submitted.
- 17. Charubala, R.; Uhlmann, E.; Himmelsbach, F.; Pfleiderer, W. Helv. Chim. Acta. 1987, 70, 2028.

(Received 5 October 1993)